Shanghai Jiaolian Drug Research

Shanghai Jiaolian Drug Research is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in the research of treatments for type 2 diabetes and obesity, leveraging expertise in G protein-coupled receptor (GPCR) targeting. Their research efforts have historically focused on developing oral agonists and inhibitors that regulate glucose metabolism and insulin secretion. Shanghai Jiaolian operates primarily as a research-driven entity, often seeking to advance candidates through early-stage development before partnering for clinical trials.